Journal of Biomolecular Screening

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rees, S.
Right arrow Articles by Beresford, I. J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rees, S.
Right arrow Articles by Beresford, I. J.M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Biomolecular Screening, Vol. 6, No. 1, 19-27 (2001)
DOI: 10.1177/108705710100600104

Development of a Homogeneous MAP Kinase Reporter Gene Screen for the Identification of Agonists and Antagonists at the CXCR1 Chemokine Receptor

Stephen Rees

Molecular Discovery, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Duncan P. Martin

Receptor Pharmacology, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Sarah V. Scott

Molecular Discovery, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Sue H. Brown

Molecular Pharmacology Research Units, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Neil Fraser

Molecular Pharmacology Research Units, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Celestine O'Shaughnessy

Molecular Pharmacology Research Units, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Isabel J.M. Beresford

Receptor Pharmacology, Glaxo Wellcome Medicines Research Centre, Hert-fordshire, UK

Agonist activity at G protein-coupled receptors (GPCRs) that regulate heterotrimeric G proteins of the G{alpha}i/o or Gaq families has been shown to result in activation of the mitogen-activated protein (MAP) kinase cascade. To facilitate compound screening for these classes of GPCR, we have developed a reporter gene that detects the activation of the ternary complex transcription factor Sapla following MAP kinase activation. In contrast to other reporter gene assays for G{alpha}i/o-coupled GPCRs, the MAP kinase reporter generates an increase in signal in the presence of agonist. The reporter gene has been transfected into Chinese hamster ovary cells to generate a "host" reporter gene-containing cell line. The G{alpha}i-coupled human CXCR1 chemokine receptor was subsequently transfected into this cell line in order to develop a 384-well format screen for both agonists and antagonists of this receptor. Agonists activated the reporter gene with the expected rank order of potency and with similar concentration dependence as seen with the regulation of other signal transduction cascades in mammalian cells: interleukin-8 (IL-8) (pEC50 = 7.0 ± 0.1) > GCP-2 (pEC50 = 6.3 ± 0.1) > NAP-2 (pEC50 < 6). CXCR1-mediated activation of MAP kinase was inhibited by pertussis toxin and the MEK inhibitor PD98059, demonstrating that receptor activation of MAP kinase is due to pertussis toxin-sensitive G{alpha}/i/o-family G proteins to cause the activation of MEK kinase. Using the 384-well format, assay performance was unaffected by solvent concentrations of 0.5% ethanol, 0.15% glycerol, or 1% DMSO. Signal crosstalk between adjacent wells was less than 1%. The assay exhibited a Z factor of 0.53 and a coefficient of variation of response to repeated application of IL-8 (100 nM) of 15.9%.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J Biomol ScreenHome page
D. L. Graham, N. Bevan, P. N. Lowe, M. Palmer, and S. Rees
Application of {beta}-Galactosidase Enzyme Complementation Technology as a High Throughput Screening Format for Antagonists of the Epidermal Growth Factor Receptor
J Biomol Screen, December 1, 2001; 6(6): 401 - 411.
[Abstract] [PDF]